Sector News

Coronavirus tracker: Alexion launches trial; Lilly, BMS extend help; Trump offers to treat British PM

April 7, 2020
Life sciences

Two biopharmas, Alexion Pharmaceuticals and Karyopharm, are trialing possible treatments while Eli Lilly and Bristol Myers Squibb are offering to help the unemployed stay on their meds.

Meanwhile, President Donald Trump offered U.K. Prime MInister Boris Johnson, in the ICU with COVID-19, unproven treatments. And news emerged that Trump himself holds a small financial interest in Sanofi, which makes an off-patent brand of hydroxychloroquine.

India is reportedly retracting export bans on 13 active pharmaceutical ingredients and finished formulations, and hydroxychloroquine may be included.

As of Tuesday, the number of global confirmed cases had surpassed 1.36 million, according to Johns Hopkins University’s real-time dashboard, and nearly 76,000 people had died.

See all of FiercePharma’s COVID-19 coverage here

By Eric Sagonowsky, Kyle Blankenship, Angus Liu, Conor Hale

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”